Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Summit Therapeutics PLC (SMMT) had Return on Tangible Equity of -164.36% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-1.08B |
|
-- |
|
-- |
|
$1.09B |
|
$-1.09B |
|
$14.84M |
|
$-1.08B |
|
$-1.08B |
|
$-1.08B |
|
$-1.08B |
|
$-1.08B |
|
$-1.08B |
|
$-1.09B |
|
$-1.09B |
|
747.70M |
|
747.70M |
|
$-1.44 |
|
$-1.44 |
|
| Balance Sheet Financials | |
$720.30M |
|
$1.06M |
|
$30.88M |
|
$751.18M |
|
$72.99M |
|
-- |
|
$19.33M |
|
$92.32M |
|
$658.86M |
|
$656.86M |
|
$658.86M |
|
775.37M |
|
| Cash Flow Statement Financials | |
$-322.93M |
|
$-174.31M |
|
$617.53M |
|
$105.19M |
|
$225.58M |
|
$120.39M |
|
$732.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-323.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-163.86% |
|
|
Return on Tangible Equity |
-164.36% |
-143.72% |
|
-163.86% |
|
$0.85 |
|
$-0.43 |
|
$-0.43 |
|